RxDoctor Payments Data

Fredrick Weinberg, MD

Cardiovascular Disease · Princeton, NJNPI 1578603692

Payments from drug & device makers

$2,979in general payments, 2019–2025

Across 71 payments — averaging $41.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Amgen$830
  • Merck$225
  • Boehringer Ingelheim$141
  • Johnson & Johnson$110
  • E.r. Squibb & Sons, L.L.C.$105
  • plus $222 from 7 others

What the payments were for

  • Travel & lodging$87729%
  • Food & beverage$2,10271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,979 in reported general payments places this provider in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$185,612
Medicare patients
2,133
Services billed
4,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban258$313,167
EntrestoSacubitril/Valsartan41$67,601
XareltoRivaroxaban59$67,580
Repatha SureclickEvolocumab30$41,672
JardianceEmpagliflozin24$37,674
OzempicSemaglutide19$17,149
Praluent PenAlirocumab12$12,361
Dofetilide20$5,714
Metoprolol Succinate211$4,217
Rosuvastatin Calcium131$2,454
Amiodarone Hcl51$2,145
Atorvastatin Calcium139$1,959
ClopidogrelClopidogrel Bisulfate52$883
Digoxin26$816
Lisinopril58$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$313,167258 claims
NovartisEntresto$55$67,60141 claims
Johnson & JohnsonXarelto$110$67,58059 claims
Boehringer IngelheimJardiance$141$37,67424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →